Cerebrospinal Fluid Glycoproteins in Schizophrenia
ROBERT J. CAMPBELL M.D.1,
SAMUEL BOGOCH M.D., PH.D.2,
MICHAEL J. SCOLARO M.D.3, , and
PETER C. BELVAL 4
1 Director of the Psychiatric Research Program, St. Vincent's Hospital and Medical Center of New York, 153 West 11th Street, New York, N. Y. 10011
2 St. Vincent's, Hospital and Medical Center of New York, 153 West 11th Street, New York, N. Y. 10011
3 Director, Foundation for Research on the Nervous System, Boston, Mass.
4 Foundation for Research on the Nervous System, Boston, Mass.
A double-blind clinical and chemical study of 131 hospitalized psychotic patients, totally removed geographically from the center at which chemical analyses were performed, demonstrated an inverse relationship between the quantity of cerebrospinal fluid glycoprotein neuraminic acid and the severity of schizophrenia, with a high concordance between chemical levels, changes in clinical condition, and family history. In addition, changes in cerebrospinal fluid glycoprotein hexose were related inversely to clinical estimates of depression.
